Published on 30 Mar 2024 on Simply Wall St. via Yahoo Finance

Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook

Today is shaping up negative for HOOKIPA Pharma Inc. (NASDAQ:HOOK) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After the downgrade, the four analysts covering HOOKIPA Pharma are now predicting revenues of US$27m in 2024. If met, this would reflect a major 34% improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 34% to US$0.55 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$35m and losses of US$0.51 per share in 2024. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.